•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022, with revenues reaching RMB 15.3 billion (USD 2.24 billion), up 20.17% year-on-year (YOY). Net profits rose 21.71% YOY to RMB 5.28 billion (USD 773 million). Business Segments R&D InvestmentMindray invested RMB 1.45 billion (USD 212…
•
JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series B financing rounds, raising a total of RMB 700 million (USD 102.5 million). Investors include SinoRock, Guanghua Wutong Equity Investment Fund, YuanHengLiZhen, Weigao Holding, and HM Capital. The funding follows a Series A round led…
•
China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for equecabtagene autoleucel (CT103A), a BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, for the treatment of neuromyelitis optica spectrum disorder (NMOSD). This marks the first global trial of a BCMA…
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues to RMB 10.22 billion (USD 1.49 billion) for H1 2022, with net profits falling 24.12% YOY to RMB 2 billion (USD 292.8 million). The company attributed the downturn to volume-based procurement (VBP) price cuts, inclusion…
•
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for its furmonertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, targeting exon 20 insertion mutated non-small cell lung cancer (NSCLC). Drug ProfileFurmonertinib received conditional market approval from the NMPA in…
•
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd, trastuzumab deruxtecan), a HER2 antibody drug conjugate (ADC), has been accepted for review by the Center for Drug Evaluation (CDE) in China. The filing seeks approval for the treatment of adult patients with unresectable or…
•
The National Healthcare Security Administration (NHSA) has released a draft proposal titled “Notice on Carrying out Special Treatment of Oral Implant Medical Service Charges and Consumables Prices,” seeking public feedback until August 27, 2022. The initiative aims to address issues such as irregular charges and heavy cost burdens in the…
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, has released its 2022 interim financial report. The report reveals a year-on-year (YOY) decline in total revenue and gross profits, alongside a significant reduction in net losses and continued growth in the number of…
•
WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement of construction on a new manufacturing site in Delaware, United States. The 190-acre campus in Middletown, first announced in June 2021, will serve as STA’s second facility in the US. Key Details of the New…
•
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million (USD 14.6 million) in a Series C+ financing round. The funding was backed by Guoyao Zhongjin (Shanghai) Medical Health Investment, ZhangKeHeRun Fund, Lingang Lanwan Private Equity Fund, and SPINNOTEC/Haiwang Capital. With this latest round, ZhenGe…
•
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in revenue for the 2022 interim period, a 103.5% year-on-year (YOY) increase. The growth was driven by sales of commercialized products and licensing income. R&D investment reached RMB 827.4 million (USD 121.5 million). Product PipelineHenlius’s pipeline…
•
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi in a Series A+ financing round led by existing investors. The funds will be used to accelerate a Phase I clinical study and pre-clinical research, expand the product pipeline, and enhance the technology platform. Company…
•
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and Gilead’s Kite Pharma, has received another clinical trial approval for its anti-CD19 chimeric antigen receptor (CAR) T therapy Yescarta (axicabtagene ciloleucel). The new indication targets adult large B-cell lymphoma (r/r LBCL) that…
•
Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an undisclosed amount of money in a Series B1 financing round. The round was solely led by AstraZeneca and CICC’s first joint global medical fund. Proceeds will be used to expand its product pipeline for women’s…
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply agreement with US pharmaceutical giant Pfizer. Under the agreement, Huahai Pharma will provide formulation contract production services for Pfizer’s COVID-19 therapy Paxlovid in mainland China. Financial details of the deal were not disclosed. Paxlovid OverviewPaxlovid…
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment and dosing of all subjects in a Phase II clinical study for its ReCOV, a recombinant protein COVID-19 vaccine, with Pfizer’s mRNA vaccine Comirnaty as a control. The study, approved in the Philippines on August…
•
China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization (CDMO) with a business unit in Shanghai, has reportedly raised close to RMB 250 million (USD 36.7 million) in a Series B financing round. The round was led by Shanghai Biomedicine Fund and included contributions…
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in a Phase I/II clinical study for its therapeutic candidate STP705 in facial squamous cell carcinoma in situ (isSCC). The study is expected to be completed during Q1 2023. Study Design and ObjectivesThe open-label, dosage escalation…
•
The National Health Commission (NHC) and National Development and Reform Commission (NDRC), along with multiple other bureaus, have released the “Guiding Opinions on Further Improving and Implementing Active Reproductive Support Measures.” The aim is to enhance prenatal and postnatal care services, develop the universal childcare service system, and improve the…